21.6103.30% ( +0.690 )
Trading: Oct 14, 11:26:45 (EDT)Current ValuationThe current P/E ratio is -23.35, below the reasonable range, cheaper than 87.47% of the time in the past 3 years, and the industry ranks 47/58, the industry Median -2.09.
-23.35xP/E
$20.92Stock price
$-0.90Earnings per share
-23.35xP/E
Stock price$20.92Earnings per share$-0.90
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -3.48x
- Typical range
- -20.08x–-0.86x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
010203040
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
LZAGYUSLonza | -345.22x | -- | $47.53B |
CRLUSCharles River Laboratorie | -59.86x | 242.15% | $14.27B |
TEMUSTempus AI | -48.10x | 1.10% | $12.24B |
AVTRUSAvantor | -18.20x | 144.24% | $10.52B |
TXGUS10X Genomics | -124.51x | 107.10% | $9.35B |
BRKRUSBruker | -80.08x | 7.71% | $8.56B |
ABCLUSAbcellera Biologics | -24.82x | 36.29% | $4.09B |
ADPTUSAdaptive Biotechnologies | -63.18x | 39.25% | $4.03B |
FTREUSFortrea | -23.35x | 93.77% | $1.99B |
MRVIUSMaravai LifeSciences | -21.91x | 64.44% | $1.70B |
PSNLUSPersonalis | -15.79x | 18.68% | $1.69B |
AZTAUSAzenta | -13.50x | 177.69% | $1.66B |
ALMRUSAlamar Biosciences | -32.87x | 80.55% | $1.63B |
CYRXUSCryoport | -18.92x | 156.25% | $858.50M |
DNAUSGinkgo Bioworks | -2.72x | 35.20% | $791.92M |
CTKBUSCytek Biosciences | -8.63x | 33.98% | $695.41M |
OABIUSOmniAb | -15.44x | 35.96% | $683.33M |
PACBUSPacific Biosc California | -4.85x | 75.69% | $637.20M |
EVOUSEvotec SE | -2.09x | 382.97% | $477.76M |
TKNOUSAlpha Teknova | -26.32x | 5.80% | $441.32M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
